Search results
Showing 301 to 315 of 381 results for lung cancer
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Discontinued Reference number: GID-TA11442
Pharyngeal electrical stimulation for neurogenic dysphagia (HTG709)
Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.
View recommendations for HTG709Show all sections
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655.
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
This guidance has been updated and replaced by NICE technology appraisal guidance 1071.
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-TA11569
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
This guidance has been updated and replaced by NICE technology appraisal guidance 1021.
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
This guidance has been updated and replaced by NICE technology appraisal guidance 713.
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
This guidance has been updated and replaced by NICE technology appraisal guidance 1103.
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Discontinued Reference number: GID-TA11302
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.